Alnylam Pharma (ALNY) Posts Smaller-than-Expected Q1 Loss
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $228.61 --0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
ZTO, AMMX, AFIB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.22), $0.25 better than the analyst estimate of ($1.47). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $30.15 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
- ZIM Integrated Shipping Services Ltd. (ZIM) Tops Q2 EPS by 82c
- Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
